Back
Orthofix Medical 10K Form
Sell
32
OFIX
Orthofix Medical
Last Price:
$17.36
Seasonality Move:
7.1%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2024-05-07 | 10Q | OFIX/Orthofix Medical Quarterly |
2023-11-08 | 10Q | OFIX/Orthofix Medical Quarterly |
2023-08-08 | 10Q | OFIX/Orthofix Medical Quarterly |
2023-05-09 | 10Q | OFIX/Orthofix Medical Quarterly |
2022-11-03 | 10Q | OFIX/Orthofix Medical Quarterly |
2022-08-05 | 10Q | OFIX/Orthofix Medical Quarterly |
Receive OFIX News And Ratings
See the #1 stock for the next 7 days that we like better than OFIX
OFIX Financial Statistics
Sales & Book Value
Annual Sales: | $746.6M |
---|---|
Cash Flow: | $5.9M |
Price / Cash Flow: | 0 |
Annual Sales: | $13.76 |
Price / Book: | 1.27 |
Profitability
EPS (TTM): | -3.13000 |
---|---|
Net Income (TTM): | $-119M |
Gross Margin: | $486.3M |
Return on Equity: | -20.83% |
Return on Assets: | -13.26% |
Orthofix Medical Earnings Forecast
Key Orthofix Medical Financial Ratios
-
The Gross Profit Margin over the past 32 years for OFIX is 65.13%.
-
The Selling, General & Administrative Expenses for OFIX have been equal to 71.04% of Gross Profit Margin.
-
The Research & Development expenses have been 10.75% of Revenue.
-
The Interest Expense is -5.70% of Operating Income.
-
The Net Earning history of OFIX is -20.28% of Total Revenues.
-
Per Share Earnings over the last 33 years have been positive in 21 years.
Orthofix Medical Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Health Care Equipment & Supplies |
Sector: | Health Care |
Current Symbol: | OFIX |
Website: | orthofix.com |
Debt
Debt-to-Equity Ratio: | 0.23 |
---|---|
Current Ratio: | 2.39 |
Quick Ratio: | 0.96 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 0 |
OFIX Technical Analysis vs Fundamental Analysis
Sell
32
Orthofix Medical (OFIX)
is a Sell
Is Orthofix Medical a Buy or a Sell?
-
Orthofix Medical stock is rated a SellThe current Orthofix Medical [OFIX] share price is $17.43. The Score for OFIX is 32, which is 36% below its historic median score of 50, and infers higher risk than normal.